Update on the management of chemotherapy-induced nausea and vomiting

Journal of Infusion Nursing

Volumn 29, Issue 5, 2006, Pages 283-292

  Viale, Pamela Hallquist ^a,b  

^a Camino Medical Group   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZAMIDE; BENZODIAZEPINE DERIVATIVE; CANNABINOID DERIVATIVE; CANNABIS DERIVATIVE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE; DOPAMINE RECEPTOR; DOXORUBICIN; GRANISETRON; LONG ACTING DRUG; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROTRANSMITTER; ONDANSETRON; PALONOSETRON; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; PROMETHAZINE; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DRUG COST; DRUG EFFECT; DRUG INDICATION; GASTROINTESTINAL SYMPTOM; HICCUP; HUMAN; HYPERGLYCEMIA; INSOMNIA; MEMORY DISORDER; NAUSEA; NAUSEA AND VOMITING; NURSING PRACTICE; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; VOMITING;

EID: 33750082728     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200609000-00007     Document Type: Review

References (41)

1. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.
2. Coates A, Abraham S, Kaye SB, et al. On the receiving end: patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203-208.
3. Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7:189-195.
4. Aapro M. Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin. 2005;21:885-897.
5. Grunberg SM, Hansen M, Deuson R, et al. Incidence and impact of nausea/vomiting with modern antiemetics: perception vs. reality [abstract 996]. Presented at 2002 ASCO Annual Meeting. Available at: http:// peoplelivingwithcancer.org/ac/1,1003,_12-002636-00_18-0016-00_19-00996,00.asp. Accessed February 12, 2006.
6. Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1,413 patients treated in community clinical practices. J Pain Symptom Manage. 2000;20:113-121.
7. Viale PH. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics. Clin J Oncol Nurs. 2005;9:77-84.
8. Bender CM, McDaniel RW, Murphy-Ende K, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2002;6:94-102.
9. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8:187-198.
10. Stewart DJ, Dahrouge S, Coyle D, Evans WK. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol. 1999;17:344-351.
11. Hesketh PJ. Understanding the pathobiology of chemotherapy-induced nausea and vomiting: providing a basis for therapeutic progress. Oncology. 2004;18(10 Suppl 6):9-14.
12. Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003;39:1074-1080.
13. Dibble SL, Israel J, Nussey B, Casey K, Luce J. Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum. 2003;30:E40-E47.
14. Doherty KM. Closing the gap in prophylactic antiemetic therapy: Patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs. 1999;3:113-119.
15. Liaw CC, Chang HK, Liau CT, et al. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. Am J Clin Oncol. 2003;26(1):12-15.
16. Gralla RJ, Carides AD, Ianus J, Elmer M, Evans JK, Horgan KJ. The oral neurokinin-1 antagonist aprepitant added to standard antiemetics provided equal efficacy in female and male patients receiving highly emetogenic chemotherapy: combined data from two phase III clinical trials [abstract 636]. Poster presented at San Antonio Breast Cancer Symposium; December 2003; San Antonio, Tex.
17. Goodman M. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. Oncol Nurs Forum. 1997;24(Suppl 7):20-32.
18. Wickham R. Management of intractable nausea and vomiting. Clin J Oncol Nurs. 2004;8:91-93.
19. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 2003;11(3):137-143.
20. Marinol Prescribing Information. Solvay Pharmaceuticals Marinol Web site. Available at: http://www.marinol.com/. Accessed on January 31, 2006.
21. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol. 2000;18:3409-3422.
22. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289-1294.
23. DiVall MV, Cersosimo RJ. Palonosetron: a novel 5-HT3 receptor antagonist for chemotherapy-associated nausea and vomiting. Formulary. 2003;38:414-430.
24. Aloxi™ [package insert]. Bloomington, Minn: MGI Pharma, Inc; 2003.
25. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005;39:77-85.
26. Emend® (aprepitant) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2005.
27. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol. 2004;44:215-223.
28. Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005;55(6):609-616.
29. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822-2830.
30. National Comprehensive Cancer Network. Antiemesis: clinical practice guidelines in oncology v.1.2006. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/antiemesis.pdf. Accessed January 28, 2006.
31. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005;13(7):529-534.
32. Multinational Association for Supportive Care in Cancer. Antiemetic Guideline Consensus. Available at: http://www.mascc.org/ktml2/images/uploads/ Resource_centers/MASCC_Guidelines_Update_9_05.pdf. Accessed January 28, 2006.
33. Aapro MS, Macciocchi A, Gridelli C. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol. 2005;3(5):369-374.
34. Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer. 2005;13:85-96.
35. Lindley C, Goodin S, McCune J, et al. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol. 2005;28(3):270-276.
36. Roila F, Warr D, Clark-Snow RA, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005;13:104-108.
37. Bell CF, Foley KA, Pelissier JM, Hu HX, Markson LE, Berger ML. Cost consequence model: assessing the use of aprepitant vs. standard anti-emetic therapy in cancer patients undergoing highly emetogenic chemotherapy [abstract]. Poster presented at Multinational Association of Supportive Care in Cancer; June 2004; Miami, Fla.
38. Stewart DJ, Dahrouge S, Coyle D, Evans WK. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol. 1999;17:344-351.
39. Shah AK, Gallagher S, Latimer L, Cullen M, Hunt TL. Lack of effect of aprepitant (APR) on the pharmacokinetics (PK) and safety of palonosetron (Palo) [abstract PII-101]. Poster presented at American Society for Clinical Pharmacology and Therapeutics Conference; 2004; Miami, Fla.
40. Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer. 2005;45(6):857-860.
41. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guidelines for Antiemetics in Oncology: Update 2006. J Clin Oncol. 2006; 24(18):2932-2947.